The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Theravance Biopharma Inc shares valued at $809,250 were purchased by ERAN BROSHY on Nov 11 ’25. At $17.98 per share, ERAN BROSHY acquired 45,000 shares.
Also, Farnum Rhonda sold 10,000 shares, netting a total of over 113,870 in proceeds. Following the sale of shares at $11.39 each, the insider now holds 326,918 shares.
Before that, RHONDA FARNUM had added 10,000 shares to its account. In a trade valued at $113,869, the Officer bought Theravance Biopharma Inc shares for $11.39 each.
As published in their initiating research note from B. Riley Securities on September 12, 2025, Theravance Biopharma Inc [TBPH] has been a Buy and the price target has been revised to $28. Analysts at Leerink Partners downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in early August. As of April 12, 2024, BTIG Research has initiated its “Buy” rating for TBPH. Earlier on January 08, 2024, Evercore ISI downgraded its rating. Their new recommendation was “an In-line” for TBPH stock which previously was a “an Outperform”.
Analyzing TBPH Stock Performance
On last trading session, Theravance Biopharma Inc [NASDAQ: TBPH] rose 0.96% to $17.9. The stock’s lowest price that day was $17.61, but it reached a high of $18.21 in the same session. During the last five days, there has been a drop of approximately -0.28%. Over the course of the year, Theravance Biopharma Inc shares have jumped approximately 88.62%. Shares of the company reached a 52-week high of $18.96 on 11/11/25 and a 52-week low of $7.90 on 04/07/25.
Support And Resistance Levels for Theravance Biopharma Inc (TBPH)
According to the 24-hour chart, there is a support level at 17.60, which, if violated, would cause prices to drop to 17.31. In the upper region, resistance lies at 18.20. The next price resistance is at 18.51. RSI (Relative Strength Index) is 65.79 on the 14-day chart, showing neutral technical sentiment.
Is Theravance Biopharma Inc subject to short interest?
Stocks of Theravance Biopharma Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.14 million shares to 5.08 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 4.95 million shares. A jump of 2.66% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 17.2 of the overall float, the days-to-cover ratio (short ratio) jumped to 17.2.
Which companies own the most shares of Theravance Biopharma Inc (TBPH)?
In terms of Theravance Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, down nearly -15.4% from the previous closing price of $17.73. Analysts anticipate Theravance Biopharma Inc stock to reach 21 by 2025, with the lowest price target being 10. In spite of this, 3 analysts ranked Theravance Biopharma Inc stock as Buy at the end of 2025. On May 23, 2022, SVB Leerink assigned a price target of “an Outperform” to the stock and initiated coverage with a $12.
